InDex Pharmaceuticals Holding AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was SEK 26.79 million compared to SEK 11.31 million a year ago. Net loss was SEK 3.45 million compared to SEK 28.25 million a year ago. Basic loss per share from continuing operations was SEK 0.01 compared to SEK 0.05 a year ago.
For the nine months, revenue was SEK 66.43 million compared to SEK 3.1 million a year ago. Net loss was SEK 44.03 million compared to SEK 80.24 million a year ago. Basic loss per share from continuing operations was SEK 0.08 compared to SEK 0.16 a year ago.